Literature DB >> 18446461

Preparation of spherical crystal agglomerates of naproxen containing disintegrant for direct tablet making by spherical crystallization technique.

A Nokhodchi1, M Maghsoodi.   

Abstract

The purpose of this research was to obtain directly compressible agglomerates of naproxen containing disintegrant by spherical crystallization technique. Acetone-water containing hydroxypropyl celloluse (HPC) and disintegrant was used as the crystallization system. In this study croscarmellose sodium (Ac-Di-Sol) was employed as disintegrant. The agglomerates were characterized by differential scanning calorimetry (DSC), powder X-ray diffraction (XRPD), and scanning electron microscopy and were evaluated for flow, packing and tableting properties and drug release. The growth of particle size and the spherical form of the agglomerates resulted in formation of products with good flow and packing properties. The improved compaction properties of the agglomerated crystals were due to their fragmentation occurred during compression. DSC and XRPD studies showed that naproxen particles, crystallized in the presence of HPC and Ac-Di-Sol did not undergo structural modifications. The dissolution rate of naproxen from tablets made of naproxen-(Ac-Di-Sol) agglomerates was enhanced significantly because of including the disintegrant in to the particles. This was attributed to an increase in the surface area of the practically water insoluble drug is exposed to the dissolution medium. In conclusion the spherical crystallization technique developed in this study is suitable for obtaining agglomerates of drug with disintegrant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446461      PMCID: PMC2976892          DOI: 10.1208/s12249-007-9019-3

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  5 in total

1.  THE FLOW PROPERTIES OF MAGNESIA.

Authors:  N PILPEL
Journal:  J Pharm Pharmacol       Date:  1964-11       Impact factor: 3.765

2.  Effect of Explotab on the tabletability of a poorly soluble drug.

Authors:  N Muñoz; C Ferrero; A Muñoz-Ruiz; M V Velasco; M R Jiménez-Castellanos
Journal:  Drug Dev Ind Pharm       Date:  1998-08       Impact factor: 3.225

3.  Determination of tablet strength by the diametral-compression test.

Authors:  J T Fell; J M Newton
Journal:  J Pharm Sci       Date:  1970-05       Impact factor: 3.534

4.  Ibuprofen agglomerates preparation by phase separation.

Authors:  M Jbilou; A Ettabia; A M Guyot-Hermann; J C Guyot
Journal:  Drug Dev Ind Pharm       Date:  1999-03       Impact factor: 3.225

5.  Preparations of agglomerated crystals of polymorphic mixtures and a new complex of indomethacin-epirizole by the spherical crystallization technique.

Authors:  Y Kawashima; S Y Lin; M Ogawa; T Handa; H Takenaka
Journal:  J Pharm Sci       Date:  1985-11       Impact factor: 3.534

  5 in total
  4 in total

1.  Preparation and In Vitro Evaluation of Ibuprofen Spherical Agglomerates.

Authors:  Nagaraju Ravouru; Subhash Chandra Bose Penjuri; Saritha Damineni; Raja Lakshmi Muni; Srikanth Reddy Poreddy
Journal:  Turk J Pharm Sci       Date:  2018-04-02

2.  Optimization of the Critical Parameters of the Spherical Agglomeration Crystallization Method by the Application of the Quality by Design Approach.

Authors:  Orsolya Gyulai; Anita Kovács; Tamás Sovány; Ildikó Csóka; Zoltán Aigner
Journal:  Materials (Basel)       Date:  2018-04-20       Impact factor: 3.623

3.  The Impact of Amorphisation and Spheronization Techniques on the Improved in Vitro & in Vivo Performance of Glimepiride Tablets.

Authors:  Rana Refaat Makar; Randa Latif; Ehab Ahmed Hosni; Omaima Naim El Gazayerly
Journal:  Adv Pharm Bull       Date:  2017-12-31

4.  Formulation of cilostazol spherical agglomerates by crystallo-co-agglomeration technique and optimization using design of experimentation.

Authors:  Sanjeevani Shekhar Deshkar; Govind R Borde; Rupali N Kale; Balasaheb A Waghmare; Asha Biju Thomas
Journal:  Int J Pharm Investig       Date:  2017 Oct-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.